Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non-Current Assets (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Other Non-Current Assets for 14 consecutive years, with $13.7 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 12.16% to $13.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.7 million through Dec 2025, up 12.16% year-over-year, with the annual reading at $13.7 million for FY2025, 12.16% up from the prior year.
  • Other Non-Current Assets hit $13.7 million in Q4 2025 for Ani Pharmaceuticals, up from $12.5 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $16.1 million in Q3 2023 to a low of $2.2 million in Q4 2021.
  • Historically, Other Non-Current Assets has averaged $9.8 million across 5 years, with a median of $11.4 million in 2022.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 55.93% in 2021 and later surged 415.24% in 2022.
  • Year by year, Other Non-Current Assets stood at $2.2 million in 2021, then soared by 415.24% to $11.4 million in 2022, then grew by 6.26% to $12.1 million in 2023, then increased by 1.23% to $12.2 million in 2024, then grew by 12.16% to $13.7 million in 2025.
  • Business Quant data shows Other Non-Current Assets for ANIP at $13.7 million in Q4 2025, $12.5 million in Q3 2025, and $8.2 million in Q2 2025.